Publication:
Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction

dc.contributor.authorM. C. Kneubilen_US
dc.contributor.authorJ. Brolloen_US
dc.contributor.authorE. Botterien_US
dc.contributor.authorG. Curiglianoen_US
dc.contributor.authorN. Rotmenszen_US
dc.contributor.authorA. Goldhirschen_US
dc.contributor.authorV. Lohsiriwaten_US
dc.contributor.authorA. Manconien_US
dc.contributor.authorS. Martellaen_US
dc.contributor.authorB. Santilloen_US
dc.contributor.authorJ. Y. Petiten_US
dc.contributor.authorM. Rietjensen_US
dc.contributor.otherIstituto Europeo di Oncologiaen_US
dc.contributor.otherUniversita degli Studi di Milanoen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-10-19T05:30:07Z
dc.date.available2018-10-19T05:30:07Z
dc.date.issued2013-03-01en_US
dc.description.abstractBackground: A small but significant proportion of patients with breast cancer (BC) will develop loco-regional recurrence (LRR) after immediate breast reconstruction (IBR). The LRR also varies according to breast cancer subtypes and clinicopathological features. Methods: We studied 1742 consecutive BC patients with IBR between 1997 and 2006. According to St Gallen conference consensus 2011, its BC approximations were applied to classify BC into five subtypes: estrogen receptor (ER) and/or progesterone receptor (PgR) positive, HER2 negative, and low Ki67 (<14%) [luminal A]; ER and/or PgR positive, HER2 negative and high Ki67(≥14%) [luminal B/HER2 negative]; ER and/or PgR positive, any Ki67 and HER2 positive [luminal B/HER2 positive]; ER negative, PgR negative and HER2 positive [HER2 positive/nonluminal]; and ER negative, PgR negative and HER2 negative [triple negative]. Cumulative incidences of LRR were compared across different subgroups by means of the Gray test. Multivariable Cox regression models were applied. Results: Median follow up time was 74 months (range 3-165). The cumulative incidence of LRR was 5.5% (121 events). The 5-year cumulative incidence of LRR was 2.5% for luminal A; 5.0% for luminal B/HER2 negative; 9.8% for luminal B/HER2 positive; 3.8% for HER2 non luminal; and 10.9% for triple negative. On multivariable analysis, tumor size (pT) >2 cm, body mass index (BMI) ≥25, triple negative and luminal B/HER2 positive subtypes were associated with increased risk of LRR. Conclusion: Luminal B/HER2 positive, triple negative subtypes and BMI ≥25 are independent prognostic factors for risk of LRR after IBR. © 2012 Published by Elsevier Ltd.en_US
dc.identifier.citationEuropean Journal of Surgical Oncology. Vol.39, No.3 (2013), 260-265en_US
dc.identifier.doi10.1016/j.ejso.2012.12.004en_US
dc.identifier.issn15322157en_US
dc.identifier.issn07487983en_US
dc.identifier.other2-s2.0-84874115664en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/32456
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84874115664&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleBreast cancer subtype approximations and loco-regional recurrence after immediate breast reconstructionen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84874115664&origin=inwarden_US

Files

Collections